共 211 条
[1]
Abdelraouf F(2016)Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a ‘chemosensitive’ relapse: a single-arm phase ii study (EORTC-08061) Eur J Cancer 54 35-39
[2]
Smit E(2012)Mechanisms of FGFR-mediated carcinogenesis Biochim Biophys Acta-Mol Cell Res 1823 850-860
[3]
Hasan B(2008)Role of platelet-derived growth factors in physiology and medicine Genes Dev 22 1276-1312
[4]
Menis J(2016)Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial Lancet Oncol 17 883-895
[5]
Popat S(2020)Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial Lancet Oncol 21 1224-1233
[6]
Van Meerbeeck JP(2018)OA13.03 anlotinib as third-line or further-line treatment in relapsed sclc: a multicentre, randomized, double-blind phase 2 trial J Thorac Oncol 13 S351-S352
[7]
Surmont VF(2019)P2.12-26 the impact of anlotinib for relapsed SCLC patients with brain metastases: a subgroup analysis of ALTER 1202 J Thorac Oncol 14 S823-S824
[8]
Baas P(2019)Overall survival (OS) update in ALTER 1202: anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC) Ann Oncol 30 618-627
[9]
O’Brien M(2020)Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies J Thorac Oncol 15 669-676
[10]
Ahmad I(2003)The biology of VEGF and Its receptors Nat Med 9 108-112